Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company
focused on skin and hair health (“Carmell” or the “Company”), today
announced it will host an Investor Webinar titled “Unveiling the
Secretome: On the Eve of Product Launch” on March 20, 2024 at 3:00
PM ET to discuss Carmell Secretome™, the biggest technological
revolution in regenerative skin and haircare to the fast-growing
~$500 billion aesthetics industry. To register, click here.
The event will feature Rajiv Shukla, Chairman
& CEO of Carmell, joined by key opinion leaders (KOLs), Dr
Gilles Spenlehauer, PhD (former Worldwide head of research for
L’Oreal, the world’s #1 cosmetics company) and Leonard Miller MD,
FACS, FRCS (Clinical Instructor at Harvard Medical School, Founder
of Boston Center for Plastic Surgery). Both KOLs are also advisors
on Carmell’s Scientific Advisory Board.
Carmell's Secretome technology delivers 1000+
growth factors, proteins and peptides extracted from allogeneic
human platelets in a twelve-month shelf-stable and biologically
active formulation. Carmell’s technology was previously being
developed as a BLA and has Phase 2 human clinical data supporting
safety and efficacy. In comparison, other aesthetic products
feature 1-2 synthetic proteins with sparse evidence of clinical
efficacy.
Besides the Carmell Secretome, the Company has
also developed a novel nanoformulation with particles ~1000x
smaller than red blood cells enabling superior permeability of its
ingredients into the stratum corneum.
Carmell aims to launch a limited-edition product
this month followed by 9 other skincare products over the summer
2024. The Company is also developing a line of topical haircare
products.
Discussion Agenda
- Market Opportunity
- Scientific Differentiation
- Upcoming Launch Objectives and
Timeline
- Product Candidates in Carmell’s
Portfolio
A live question and answer session will follow
the formal Press Releases.
About Rajiv ShuklaRajiv Shukla
is Chairman & CEO of Carmell Corporation. Mr. Shukla has over
20 years of operating and transaction experience in the healthcare
industry. Rajiv has served as CEO of 4 publicly listed companies
and served as Director on the Boards of 14 companies. He has
conducted over 45 healthcare equity investments including multiple
roll-ups/control investments and closed over $65 billion in
healthcare acquisitions over his career at Pfizer, where he led
Global M&A for the R&D division, and as Managing
Director/Portfolio Manager at Morgan Stanley Investment Management
and Private Equity Director at Citi Venture Capital International.
He began his career as a Management Consultant at the Boston
Consulting Group. Mr. Shukla graduated with a Bachelors in
Pharmaceutics from the Indian Institute of Technology, a Pfizer
Fellowship in Pharmaceutics from the State University of New York
and a Masters in Healthcare Management from Harvard University.
About Gilles Spenlehauer,
PhDGilles Spenlehauer, PhD, a member of Carmell
Corporation's Board of Directors, currently serves as Scientific
Director of SDTech Group, a chemical manufacturing company. Earlier
he spent 17 years at L’Oreal, the world’s biggest cosmetics company
where he served in various leadership roles – most recently as
Department Head of Science and Skills of the Future and as
Worldwide Head of Advanced Research where he led a team of 700
scientists that contributed to numerous product innovations and
were involved in scientific due diligence of acquisitions.
Before L’Oreal, Dr. Spenlehauer served as Head
of Pharmaceutical Sciences for Pfizer’s R&D operations in the
UK. He began his career as a Scientist at Rhone-Poulenc Rorer in
Paris, France. He graduated with a PhD in Biopharmacy from the
Paris-Sud University with a post-doctoral fellowship in peptides
from the Washington University in St. Louis.
About Leonard Miller, MD, FACS,
FRCSLeonard Miller, MD, FACS, FRCS, a member of Carmell
Corporation's Scientific Advisory Board (“SAB”), is a double
board-certified plastic surgeon leading the Boston Center for
Facial Rejuvenation, one of the largest providers of surgical and
non-surgical aesthetic services in the Boston Metro area and two
skin care/laser centers in Boston. With a reputation as one of
Massachusetts’s most awarded and respected plastic surgeons, Dr.
Miller has received numerous accolades over 35 years of practice.
He attended medical school in South Africa at the University of
Cape Town and received postgraduate training at Harvard Medical
School-affiliated Brigham & Women’s Hospital, Harvard Surgical
Services/Beth Israel Deaconess Hospital, Emory University
Affiliated Hospitals and Groote Schuur Hospital.
Dr. Miller serves as a Clinical Instructor in
surgery at Harvard Medical School and is a staff surgeon at Beth
Israel Deaconess and New England Baptist Hospitals. He was the
first surgeon to introduce Microneedling (Percutaneous Collagen
Induction Therapy) to the United States, revolutionizing skin
rejuvenation. Dr. Miller holds numerous patents and has co-founded
several companies in the injectable fillers and aesthetic
regenerative space.
About CarmellCarmell is a
bio-aesthetics company that utilizes the Carmell Secretome™ to
support skin and hair health. The Carmell Secretome™ consists
of a potent cocktail of growth factors and proteins extracted from
allogeneic human platelets sourced from U.S. Food and Drug
Administration-approved tissue banks. The technology underpinning
the Carmell Secretome™ has been extensively tested for safety
and efficacy, significantly surpassing standards set by the
aesthetics industry, including robust results from a prospective,
randomized, multi-center Phase 2 human trial. Besides the Carmell
Secretome™, the Company has developed a novel micellar nanoparticle
formulation that enables delivery of lipophilic and hydrophilic
ingredients without relying on the Foul Fourteen™, 14 potentially
harmful excipients that are commonly used by other companies to
impart texture, stability, and other desirable physicochemical
attributes to cosmetic products. Additionally, Carmell’s micellar
formulations do not utilize mineral or vegetable oils and are
designed to be non-comedogenic. The Company is also developing a
line of men’s products and a line of topical haircare products. All
products are tailored to meet the demanding technical requirements
of professional care providers and discerning retail consumers. For
more information, visit www.carmellcosmetics.com.
Forward-Looking StatementsThis
press release contains forward-looking statements that are based on
beliefs and assumptions and information currently available.
Forward-looking statements generally relate to future events or the
Company’s future financial or operating performance for example:
the success, cost and timing of product development activities,
including timing of initiation, completion and data readouts for
clinical trials; the potential attributes and benefits of product
candidates, including in comparison to other products on the market
for the same or similar indications; ability to compete with other
companies currently marketing or engaged in the development of
treatments for relevant indications; the size and growth potential
of the markets for product candidates and ability to serve those
markets; the rate and degree of market acceptance of product
candidates, if approved; the potential pricing of product
candidates, if approved; the Company's expected cash runway. In
some cases, you can identify forward-looking statements by
terminology such as “may”, “should”, “expect”, “intend”, “will”,
“estimate”, “anticipate”, “believe”, “predict”, “potential” or
“continue”, or the negatives of these terms or variations of them
or similar terminology. Such forward-looking statements are subject
to risks, uncertainties, and other factors which could cause actual
results to differ materially from those expressed or implied by
such forward looking statements.
These forward-looking statements are based upon
estimates and assumptions that, while considered reasonable by the
Company and its management, as the case may be, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in the section entitled “Risk Factors” in the Company’s 10-Q,
dated November 15, 2023, and other filings with the Securities and
Exchange Commission (SEC), as well as factors associated with
companies, such as the Company, that are engaged in clinical trials
in the biopharma industry, including uncertainty in the timing or
results of clinical trials and receipt of regulatory approvals for
product candidates, and in the healthcare industry, including the
impact of the COVID-19 pandemic; competition in the healthcare
industry; inability to recruit or retain a sufficient number of
patients or physicians and other employees; changes to federal and
state healthcare laws and regulations; changes to reimbursement
rates; overall business and economic conditions affecting the
healthcare industry, including conditions pertaining to health
plans and payors; failure to develop new technology and products,
if approved; and security breaches, loss of data or other
disruptions.
Nothing in this Press Release should be regarded
as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be
achieved. You should not place undue reliance on forward- looking
statements in this Press Release, which speak only as of the date
they are made and are qualified in their entirety by reference to
the cautionary statements herein. Except as required by law, the
Company does not undertake any duty to update these forward-looking
statements. This Press Release contains certain financial forecast
information of the Company. Such financial forecast information
constitutes forward-looking information and is for illustrative
purposes only and should not be relied upon as necessarily being
indicative of future results. The assumptions and estimates
underlying such financial forecast information are inherently
uncertain and are subject to a wide variety of significant
business, economic, competitive and other risks and uncertainties.
See "Forward-Looking Statements" above. Actual results may differ
materially from the results contemplated by the financial forecast
information contained in this Press Release, and the inclusion of
such information in this Press Release should not be regarded as a
representation by any person that the results reflected in such
forecasts will be achieved.
ContactBryan CassadayChief Financial
Officerbc@carmellcorp.com
Carmell (NASDAQ:CTCX)
過去 株価チャート
から 11 2024 まで 12 2024
Carmell (NASDAQ:CTCX)
過去 株価チャート
から 12 2023 まで 12 2024